Historical mrk News Stories
Merck Moves: Revolution Talks End, Gardasil Hit Up
Merck halted acquisition talks with Revolution Medicines and faces a CDC-driven reduction in HPV dosing that could cost Gardasil up to $630M in U.S. revenue. These concrete developments reshape near-term revenue expectations while highlighting Merck’s disciplined capital allocation and longer-term oncology strategy.
Merck Buys Elanco Aqua Unit for $1.3B; Animal Gain
Merck (MRK) agreed to acquire Elanco’s aquaculture business for about $1.3 billion, adding manufacturing sites and vaccine and sea‑lice products to its Animal Health division. The move arrives after Merck reported solid Q4 and full‑year 2025 results—Animal Health sales grew ~8%—and reinforces the company’s diversification and revenue mix ahead of 2026 guidance.
Merck Rally: Keytruda & Animal Health Drive Gains
Merck’s latest quarter showed strong Keytruda sales and a resilient animal health division, driving the stock higher despite conservative 2026 guidance and a near-term charge linked to the Cidara acquisition. Dividend continuity and manufacturing expansion reinforce the buy-and-hold case for income-focused investors.
Merck Ends $30B Revolution Talks, MRK Outlook 2026
Merck has formally ended acquisition talks with Revolution Medicines after a pricing deadlock. The decision underscores Merck's disciplined M&A stance under CEO Robert Davis, leaves MRK in the Dow Jones Industrial Average, and focuses investor attention on upcoming Phase I/II oncology data from Revolution in H1 2026 as a potential future catalyst.
Merck: EXZOLT Win, Guidance Miss, Animal Push 2026
Merck shares showed resilience this week as the company posted mixed 2025 guidance that fell short of analyst estimates while advancing its animal health strategy with EXZOLT approval and a major Kansas investment. Key pharmaceuticals like Keytruda remain growth drivers, but Gardasil disruptions and policy headwinds trimmed near-term revenue expectations.
Merck Eyes $70B Growth, Bids for Revolution Buyout
This week Merck (MRK) announced an upgraded long-term revenue target of $70 billion from new therapy areas, entered talks to acquire Revolution Medicines for a potential $28–$32 billion, moved to acquire U.S. rights to SENTINEL parasiticide products for roughly $400 million, and launched a Phase 3 KRAS G12C trial—events that create concrete near- and long-term catalysts for MRK stock.
Merck Poised: Winrevair EU Nod & Cidara Deal
Merck (MRK) gained traction after a Jan 2 stock bounce, driven by a CHMP recommendation expanding Winrevair's PAH label in Europe and progress on a $9.2B acquisition of Cidara Therapeutics. Both moves carry clear near- and mid-term implications for revenue and investor sentiment.
Merck Accelerates Approvals: Enlicitide, sac-TMTQ4
Merck (MRK) secured two FDA priority review vouchers for Enlicitide and sac‑TMT, in‑licensed a GLP‑1 obesity candidate from Hansoh, and won conditional FDA approval for Exzolt in cattle. These concrete regulatory and business moves shorten commercialization timelines, expand therapeutic reach into obesity, and add incremental stability from animal health—factors likely to influence MRK’s near‑term valuation and revenue mix.
Merck Surge: FDA Wins, MFN Deal, EXZOLT Boost Now!
Merck (MRK) saw several concrete catalysts this week: two FDA Priority Review vouchers for late-stage human drugs, a Most-Favored-Nation pricing pact with U.S. authorities, conditional FDA approval for a new cattle parasiticide, and financing tied to a strategic acquisition. Those events tighten approval timelines, clarify pricing risk, and strengthen the animal-health revenue base — factors that materially affect MRK’s near-term valuation and investor outlook.
Merck: Winrevair Lifts MRK; Keytruda Injunction
This week Merck (MRK) saw regulatory wins and legal setbacks: the EMA committee recommended expanding Winrevair for PAH, a German court blocked distribution of subcutaneous Keytruda, Merck’s animal-health unit secured conditional FDA approval for Exzolt in cattle, and Q3 results beat expectations—shaping near-term investor prospects.
Mercks EXZOLT Approval Boosts Animal Health Gains
Merck’s Animal Health unit secured an FDA conditional approval for EXZOLT CATTLE‑CA1 to control New World screwworm and cattle fever tick, creating a near-term product launch opportunity in Q1 2026. Strong Q2/Q3 animal health revenue and planned manufacturing investments underpin long-term growth, even as MRK shares showed muted market reaction in the past week.
Merck Boosted by U.K. Drug-Price Deal, Animal Edge
Merck (MRK) stands to benefit from a recent U.S.–U.K. agreement that raises U.K. prices for new patented medicines and offers tariff relief, strengthening its European revenue outlook and operational footing. At the same time, Merck’s animal-health business showed relative resilience versus Zoetis, supporting investor confidence in MRK within the DJ30.
Merck Rally: HIV Win, Keytruda SC, Dow Leadership!
Merck surged this week after a Phase III win for an oral two‑drug HIV regimen and European approval for Keytruda subcutaneous dosing. Those concrete clinical and regulatory milestones powered MRK stock gains that meaningfully lifted the Dow, offering investors short‑term momentum and tangible long‑term catalysts.
Merck Q3 Beats; Verona Deal, Guidance Trim Ahead!!
Merck delivered a strong Q3 led by Keytruda and Winrevair, closed the Verona Pharma acquisition for Ohtuvayre, and tightened full‑year revenue guidance — a mix that drove stock reaction even as pipeline approvals and manufacturing investments support longer‑term growth.
Merck Stretches into Obesity; Cuts Oncology Bets Now
Merck (MRK) this week struck a licensing deal to enter obesity therapeutics, paused several late‑stage oncology programs, and gained regulatory momentum in other areas. The Hansoh partnership for preclinical GLP‑1 candidate HS‑10535, EMA's favorable opinion for Welireg, and an RSV prophylactic filing highlight a strategic refocus that could reshape near‑term expectations for MRK stock.